Literature DB >> 22536808

Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study.

J N L Schouten1, F Nevens, B Hansen, W Laleman, M van den Born, M Komuta, T Roskams, J Verheij, H L A Janssen.   

Abstract

BACKGROUND: Idiopathic noncirrhotic portal hypertension (INCPH) is a rare disease in the Western world. As a result, little is known about the clinical characteristics and outcome of these patients. Survival in these patients is considered to be similar to that of the general population. AIM: To investigate the clinical manifestations, pathophysiology, outcome and determinants of survival in Western INCPH patients.
METHODS: Multicentre cohort study of INCPH patients.
RESULTS: A total of 62 patients were followed for a median time of 90 months (range 24-310). Initial manifestations leading to the diagnosis of INCPH were related to portal hypertension in 82% of the patients. Histological signs of portal blood supply disturbances were present in nearly all patients. During follow-up, 12 of 62 patients developed liver decompensation, of which four were considered for liver transplantation. One patient died in the context of variceal bleeding. Hepatocellular carcinoma was not observed during follow-up. A total of 23 patients died during follow-up, only four of them due to liver related mortality. The Kaplan-Meier estimates for overall survival were 100% (95% CI 95-100%), 78% (95% CI 67-89%) and 56% (95% CI 40-72%) at 1, 5 and 10 years respectively. Survival for INCPH was significantly decreased (P < 0.001) compared to survival of the general population. Ascites was an independent predictor of poor outcome.
CONCLUSIONS: In comparison to the general population, survival in INCPH patients is poor. Mortality is related to associated disorders and medical conditions occurring at older age. Patients rarely die due to liver related complications. Patients with ascites have a poor prognosis.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22536808     DOI: 10.1111/j.1365-2036.2012.05112.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  22 in total

1.  Idiopathic Noncirrhotic Portal Hypertension.

Authors:  Harry L A Janssen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-07

2.  Pediatric non-cirrhotic portal fibrosis: role of endoscopic management in determining long-term outcome.

Authors:  Durga Prasad; Moinak Sen Sarma; Surender Kumar Yachha; Anshu Srivastava; Ujjal Poddar
Journal:  Hepatol Int       Date:  2019-08-29       Impact factor: 6.047

Review 3.  Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options.

Authors:  Ashish Goel; Joshua E Elias; Chundamannil E Eapen; Banumathi Ramakrishna; Elwyn Elias
Journal:  J Clin Exp Hepatol       Date:  2014-07-28

Review 4.  The current clinical aspects of idiopathic portal hypertension.

Authors:  Tomohiro Tanaka; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2013-08

Review 5.  Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts.

Authors:  Dominique-Charles Valla; Dominique Cazals-Hatem
Journal:  Virchows Arch       Date:  2018-03-24       Impact factor: 4.064

Review 6.  Idiopathic portal hypertension and extrahepatic portal venous obstruction.

Authors:  Rajeev Khanna; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2018-02-20       Impact factor: 6.047

7.  Role of anticoagulant therapy in liver disease.

Authors:  Elisabeth P C Plompen; Jeoffrey N L Schouten; Harry L A Janssen
Journal:  Hepatol Int       Date:  2013-03-26       Impact factor: 6.047

Review 8.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

9.  Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension.

Authors:  Hitoshi Maruyama; Takayuki Kondo; Tadashi Sekimoto; Osamu Yokosuka
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

10.  Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension.

Authors:  Nikolaj Worm Ørntoft; Michel Blé; Anna Baiges; Jose Ferrusquia; Virginia Hernández-Gea; Fanny Turon; Marta Magaz; Søren Møller; Holger Jon Møller; Juan Carlos Garcia-Pagan; Henning Gronbaek
Journal:  Front Physiol       Date:  2021-06-11       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.